Host epithelial cell inflammatory signaling

Host epithelial cell inflammatory signaling refers to the complex network of intracellular pathways activated in epithelial cells—such as those lining the gut, lungs, and skin—in response to pathogens, allergens, or injury. These cells act as a first line of defense, utilizing pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) to detect threats and initiate the production of pro-inflammatory cytokines, chemokines, and antimicrobial peptides (Nature Reviews Immunology, 2020). Key downstream mediators include the NF-κB and MAPK pathways, which coordinate the recruitment and activation of immune cells to the site of insult (Journal of Clinical Investigation, 2018). While essential for host defense and tissue repair, dysregulated or chronic activation of these signaling pathways is a hallmark of various inflammatory and autoimmune diseases, including asthma, COPD, and inflammatory bowel disease (NIH, 2022). Therapeutic strategies often focus on modulating specific components of this signaling network, such as JAK kinases or specific cytokines, to restore homeostasis without compromising systemic immunity (StatPearls, 2023). By targeting these pathways, clinicians aim to reduce the chronic inflammation that leads to tissue remodeling and loss of organ function (PubMed, 2021).

Other names

Epithelial inflammatory responseMucosal inflammatory signalingAirway epithelial signalingIntestinal epithelial inflammatory pathwayEpithelial innate immune signaling

Inhibition of pro-inflammatory cytokine signaling, blockade of pattern recognition receptors, or modulation of intracellular transcription factor activation (e.g., NF-κB or JAK-STAT inhibition) to reduce the production of inflammatory mediators and recruitment of immune cells.